The PARADIGM International Liaison Group (PILG) is a co-creation hub acting as an operational platform to connect PARADIGM with like-minded initiatives.
These include key Innovative Medicine Initiatives and other international efforts focused on the co-development and implementation of patient engagement practices in medicines development.
The PILG supports the members of the PARADIGM consortium to create a well-defined roadmap addressing the strategic and operational needs and resources for patient engagement, focusing on the three phases targeted by PARADIGM:
Research and
priority setting
Design of
clinical trials
Early dialogues with
regulators and HTA bodies
The PILG is instrumental, agile and aligned with PARADIGM’s scope in the following ways:
provides advice to PARADIGM in developing relationships
establishes an international vision of patient engagement
reduces fragmentation and duplication
relevante of PARADIGM strategic objectives
Senior representatives of the following organisations and initiatives are a part of PILG:
+ External experts such as Dr. Violeta Stoyanova-Beninska from the Medicine Evaluation Board and chair of the Committee for Orphan Medicinal Product at the EMA and representatives from PCORI.
